ARTICLE | Company News
Carlsson Research, Merck deal
March 17, 2003 8:00 AM UTC
MRK will further develop and market Carlsson’s lead compound, ACR16 dopaminergic transmission stabilizer to treat schizophrenia. The compound completed a Swedish Phase I study in April 2002. MRK also...